OBJECTIVES/HYPOTHESIS: To determine if the various imaging modalities for distant metastasis (DM) diagnosis alters life expectancy in head and neck squamous cell carcinoma (HNSCC). STUDY DESIGN: Retrospective. METHODS: One hundred seventy patients (mean age, 59.1 years; male:female, 135:35) with HNSCC who developed DM were reviewed. The main outcome measures were the method of DM diagnosis and time from DM diagnosis to death while controlling for clinical parameters (age, gender, tobacco status, primary tumor site, initial TNM classification, number and site of DM, administration of palliative chemotherapy). RESULTS: Tumor subsites were: 40 oral cavity, 75 oropharynx, 36 larynx, 10 hypopharynx, one nasopharynx, and eight unknown primary. Of the patients, 16.5% (28/170) had distant metastasis at presentation; the remaining 142 patients were diagnosed with DM at a median of 324 days from diagnosis. Although patients diagnosed with DM by positron-emission tomography (PET) scan were more likely to have multiple DM sites (P = .0001), there were no differences in life expectancy in patients who were diagnosed with or without PET scan (median, 185 vs. 165 days, P = .833). There were no differences in life expectancy based on age, gender, site of primary tumor, or number/site of DM. The use of palliative chemotherapy resulted in a significantly longer life expectancy (median, 285 vs. 70 days; P = .001). CONCLUSIONS: Although a PET scan is more likely to diagnose multiple DM sites, there was no difference in life expectancy based on imaging modality. Patients who are symptomatic from their distant metastasis have a worse life expectancy, and palliative chemotherapy was able to increase life expectancy, even in patients who were symptomatic from the distant metastasis.
OBJECTIVES/HYPOTHESIS: To determine if the various imaging modalities for distant metastasis (DM) diagnosis alters life expectancy in head and neck squamous cell carcinoma (HNSCC). STUDY DESIGN: Retrospective. METHODS: One hundred seventy patients (mean age, 59.1 years; male:female, 135:35) with HNSCC who developed DM were reviewed. The main outcome measures were the method of DM diagnosis and time from DM diagnosis to death while controlling for clinical parameters (age, gender, tobacco status, primary tumor site, initial TNM classification, number and site of DM, administration of palliative chemotherapy). RESULTS:Tumor subsites were: 40 oral cavity, 75 oropharynx, 36 larynx, 10 hypopharynx, one nasopharynx, and eight unknown primary. Of the patients, 16.5% (28/170) had distant metastasis at presentation; the remaining 142 patients were diagnosed with DM at a median of 324 days from diagnosis. Although patients diagnosed with DM by positron-emission tomography (PET) scan were more likely to have multiple DM sites (P = .0001), there were no differences in life expectancy in patients who were diagnosed with or without PET scan (median, 185 vs. 165 days, P = .833). There were no differences in life expectancy based on age, gender, site of primary tumor, or number/site of DM. The use of palliative chemotherapy resulted in a significantly longer life expectancy (median, 285 vs. 70 days; P = .001). CONCLUSIONS: Although a PET scan is more likely to diagnose multiple DM sites, there was no difference in life expectancy based on imaging modality. Patients who are symptomatic from their distant metastasis have a worse life expectancy, and palliative chemotherapy was able to increase life expectancy, even in patients who were symptomatic from the distant metastasis.
Authors: V J Lowe; J H Boyd; F R Dunphy; H Kim; T Dunleavy; B T Collins; D Martin; B C Stack; C Hollenbeak; J W Fletcher Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544
Authors: M Lapela; A Eigtved; S Jyrkkiö; R Grénman; T Kurki; P Lindholm; J Nuutinen; E Sutinen; O Solin; I Bjornskov; P Bretlau; L Friberg; S Holm; M Jensen; H Sand Hansen; H Minn Journal: Eur J Cancer Date: 2000-05 Impact factor: 9.162
Authors: V J Lowe; F R Dunphy; M Varvares; H Kim; M Wittry; C H Dunphy; T Dunleavy; E McDonough; J Minster; J W Fletcher; J H Boyd Journal: Head Neck Date: 1997-12 Impact factor: 3.147
Authors: G Recondo; J P Armand; E Tellez-Bernal; C Domenge; M Belehradek; F De Vathaire; P Wibault; J M Richard; E Cvitkovic Journal: Laryngoscope Date: 1991-05 Impact factor: 3.325
Authors: C Jacobs; G Lyman; E Velez-García; K S Sridhar; W Knight; H Hochster; L T Goodnough; J E Mortimer; L H Einhorn; L Schacter Journal: J Clin Oncol Date: 1992-02 Impact factor: 44.544
Authors: Benjamin R Roman; Shivangi Lohia; Nandita Mitra; Marilene B Wang; Anna M Pou; F Christopher Holsinger; David Myssiorek; David Goldenberg; David A Asch; Judy A Shea Journal: Head Neck Date: 2020-01-10 Impact factor: 3.147
Authors: Andrew Rosko; Andrew Birkeland; Andrew Shuman; Mark Prince; Carol Bradford; Gregory Wolf; Francis Worden; Avraham Eisbruch; Ashok Srinivasan; Ka Kit Wong; Matthew E Spector Journal: Head Neck Date: 2017-02-25 Impact factor: 3.147
Authors: Alfio Ferlito; Missak Haigentz; Patrick J Bradley; Carlos Suárez; Primož Strojan; Gregory T Wolf; Kerry D Olsen; William M Mendenhall; Vanni Mondin; Juan P Rodrigo; Carsten C Boedeker; Marc Hamoir; Dana M Hartl; Jennifer L Hunt; Kenneth O Devaney; Lester D R Thompson; Alessandra Rinaldo; Robert P Takes Journal: Eur Arch Otorhinolaryngol Date: 2013-04-17 Impact factor: 2.503
Authors: J Madana; Gregoire B Morand; Luz Barona-Lleo; Martin J Black; Alex M Mlynarek; Michael P Hier Journal: J Otolaryngol Head Neck Surg Date: 2015-02-04
Authors: Asaf Senft; Gül Yildirim; Otto S Hoekstra; Jonas A Castelijns; C René Leemans; Remco de Bree Journal: Eur Arch Otorhinolaryngol Date: 2016-11-01 Impact factor: 2.503
Authors: Petr Szturz; Carl Van Laer; Christian Simon; Dirk Van Gestel; Jean Bourhis; Jan B Vermorken Journal: Front Oncol Date: 2020-05-06 Impact factor: 6.244